Indefinite Delivery Contract 75D30126D20713

AstraZeneca Pharmaceuticals LP was awarded a multiple-award Indefinite Delivery/Indefinite Quantity contract by the Centers for Disease Control and Prevention (CDC) on December 31, 2025, with a ceiling value of $9.3 million and a period of performance extending through February 28, 2027. This contract supports the Vaccine for Children (VFC) program, which was established under the Omnibus Budget Reconciliation Act of 1993 to provide influenza vaccines to eligible pediatric populations including Medicaid-eligible children, uninsured children, American Indian/Alaska Native children, and children whose private insurance does not cover vaccine costs. The procurement requires delivery of adult flu vaccines meeting FDA licensing requirements and specifications, with a minimum shelf life extending no earlier than June 30, 2027, and delivery to CDC centralized distribution locations in Olive Branch, Mississippi, and Clermont, Kentucky. The contract employs a firm-fixed price delivery order structure with individual contracts featuring minimum order requirements of 100 doses and maximum order quantities of 30 million doses per contract.

The CDC solicitation (75D30125R73357), posted on August 14, 2025, with proposals due August 28, 2025, was structured as a multiple-award Indefinite Delivery vehicle with a combined government ceiling across all awarded contracts of either 6 million doses or $710 million, whichever is reached first. Evaluation criteria encompassed technical compliance, pricing, and past performance factors. AstraZeneca's award reflects the company's established capabilities as a licensed pharmaceutical manufacturer with demonstrated experience supplying vaccines to federal health agencies. The solicitation included small business subcontracting goals totaling 12.17% small business participation, with designated targets for disadvantaged, HUBZone, women-owned, and service-disabled veteran-owned small business categories. No set-aside designation was applied to this procurement, consistent with AstraZeneca's classification as a large, established pharmaceutical manufacturer capable of meeting complex federal vaccine procurement requirements.